StreetInsider.com News Articles

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Fri, 17 Jul 2026 16:15:00 -0400

Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib

SAN DIEGO, July 17, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced two presentations at the European Society for Medical Oncology (ESMO) Congress 2026, taking place October 23-27, 2026, in Madrid, Spain.

"We are pleased that the overall survival results from the DENALI Part 1b study are accepted as a rapid oral

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Fri, 17 Jul 2026 16:15:00 -0400

Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib

"We are pleased that the overall survival results from the DENALI Part 1b study are accepted as a rapid oral

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Fri, 17 Jul 2026 16:15:00 -0400

Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib

"We are pleased that the overall survival results from the DENALI Part 1b study are accepted as a rapid oral

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

Fri, 17 Jul 2026 16:15:00 -0400

Rapid oral presentation to highlight overall survival data from the DENALI Part 1b study of azenosertib

"We are pleased that the overall survival results from the DENALI Part 1b study are accepted as a rapid oral

Mizuho Starts Zentalis Pharmaceuticals (ZNTL) at Outperform

Fri, 17 Jul 2026 04:25:34 -0400

Mizuho analyst Graig Suvannavejh initiates coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a Outperform rating and a price target of $8.00.

The analyst comments: “We initiate ZNTL at Outperform, $8 PT (implies ~75% upside), seeing attractive-risk/ reward ahead of a key P2 DENALI Part 2 study data readout, expected by YE26. ZNTL is developing azenosertib/azeno (an oral WEE1 inhibitor) for Cyclin E1-positive, platinum-resistant ovarian cancer (PROC), an indication of high unmet need, given only ~12 months of survival with current standard-of-care treatment. With the P2 data readout approaching, investor debates exist around azeno (e.g., prior safety data, the current competitive landscape).

Mizuho Starts Zentalis Pharmaceuticals (ZNTL) at Outperform

Fri, 17 Jul 2026 04:25:34 -0400

Mizuho analyst Graig Suvannavejh initiates coverage on Zentalis Pharmaceuticals (NASDAQ: ZNTL) with a Outperform rating and a price target of $8.00.

Form 4 Zentalis Pharmaceuticals For: Jun 16 Filed by: Skvarka Jan

Thu, 18 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260618/26666025.html

Form 4 Zentalis Pharmaceuticals For: Jun 16 Filed by: Skvarka Jan

Thu, 18 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260618/26666025.html

Form 4 Zentalis Pharmaceuticals For: Jun 16 Filed by: Johnson David Michael

Thu, 18 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260618/26666034.html

Form 4 Zentalis Pharmaceuticals For: Jun 16 Filed by: Johnson David Michael

Thu, 18 Jun 2026 16:09:00 -0400

si-local-file:///var/storage/secattach/20260618/26666034.html

Form 4 Zentalis Pharmaceuticals For: Jun 16 Filed by: Walker Luke Nathaniel

Thu, 18 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260618/26666009.html

Form 4 Zentalis Pharmaceuticals For: Jun 16 Filed by: Walker Luke Nathaniel

Thu, 18 Jun 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260618/26666009.html

Form 4 Zentalis Pharmaceuticals For: Jun 16 Filed by: Kariuki Enoch

Thu, 18 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260618/26665997.html

Form 4 Zentalis Pharmaceuticals For: Jun 16 Filed by: Kariuki Enoch

Thu, 18 Jun 2026 16:07:00 -0400

si-local-file:///var/storage/secattach/20260618/26665997.html

Form 4 Zentalis Pharmaceuticals For: Jun 16 Filed by: Myers Scott Dunseth

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665968.html

Form 4 Zentalis Pharmaceuticals For: Jun 16 Filed by: Myers Scott Dunseth

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665968.html

Form 8-K Zentalis Pharmaceuticals For: Jun 16

Thu, 18 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260618/26665848.html

Form 8-K Zentalis Pharmaceuticals For: Jun 16

Thu, 18 Jun 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260618/26665848.html

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 17:00:00 -0400

SAN DIEGO, June 01, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that on June 1, 2026, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 191,000 shares of the Company’s common stock to two (2) newly hired employees. The stock options were granted under the Zentalis Pharmaceuticals, Inc. 2022 Employment Inducement Incentive Award Plan (2022 Inducement Plan) as an inducement material to each such individual’s

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 17:00:00 -0400

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 17:00:00 -0400

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 01 Jun 2026 17:00:00 -0400

Form 4 Zentalis Pharmaceuticals For: May 26 Filed by: Campbell Shannon

Wed, 27 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260527/26557962.html

Form 4 Zentalis Pharmaceuticals For: May 26 Filed by: Campbell Shannon

Wed, 27 May 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260527/26557962.html

Form 3 Zentalis Pharmaceuticals For: May 22 Filed by: Campbell Shannon

Wed, 27 May 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260527/26557942.html